Discrepancies between tumor genomic profiling and germline genetic testing

por Pauley, K., Koptiuch, C., Greenberg, S., Kohlmann, W., Jeter, J., Colonna, S., Werner, T., Kinsey, C., Gilcrease, G., Weis, J., Whisenant, J., Florou, V., Garrido-Laguna, I.
Publicado 2022

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

por Rodon Ahnert, J., Tan, D.S.-W., Garrido-Laguna, I., Harb, W., Bessudo, A., Beck, J.T., Rottey, S., Bahary, N., Kotecki, N., Zhu, Z., Deng, S., Kowalski, K., Wei, C., Pathan, N., Laliberte, R.J., Messersmith, W.A.
Publicado 2023

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer

por Garrido-Laguna, I, Tan, A C, Uson, M, Angenendt, M, Ma, W W, Villaroel, M C, Zhao, M, Rajeshkumar, N V, Jimeno, A, Donehower, R, Iacobuzio-Donahue, C, Barrett, M, Rudek, M A, Rubio-Viqueira, B, Laheru, D, Hidalgo, M
Publicado 2010